BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
October 27, 2016 9:33 AM EDTJefferies maintained a Hold rating on PAREXEL International (NASDAQ: PRXL), and cut the price target to $67.00 (from $72.50), following the company's 1Q earnings report. EPS fell 10c below consensus and guidance midpoint. PRXL's revenue shortfall accounted for ~4c. Updated guidance reduces revenue by... More
